Evidence map›Paper›PMID 37974379›Full record

ArticleThe journal of pathology. Clinical research2024

Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma.

Ayako Ura, Takuo Hayashi, Kazumasa Komura, Masaki Hosoya, Kazuya Takamochi, Eiichi Sato, Satomi Saito, Susumu Wakai, Takafumi Handa, Tsuyoshi Saito and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pathology. Clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. X and Y Differences in Melanoma Survival Between the Sexes.Pigment cell & melanoma research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Ayako UraDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takuo HayashiDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0002-8544-9370
Kazumasa KomuraDepartment of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Masaki HosoyaDepartment of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kazuya TakamochiDepartment of General Thoracic Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Eiichi SatoDepartment of Pathology, Institute of Medical Science (Medical Research Center), Tokyo Medical University, Tokyo, Japan.
Satomi SaitoDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Susumu WakaiDivision of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
Takafumi HandaDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tsuyoshi SaitoDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-9690-8440
Shunsuke KatoDepartment of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kenji SuzukiDepartment of General Thoracic Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takashi YaoDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tokyo Metropolitan Innovative Oncology Research Group (TMIG)
Juntendo University · JPNational Center for Global Health and Medicine · JPOsaka University of Pharmaceutical Sciences · JPTokyo Medical University · JP

Funding

Japan Society for the Promotion of Science (JSPS KAKENH) 22H02842Kurozumi Medical FoundationProject for Research on Environmental and Gender-Specific Medicine E2012Takeda Science Foundation
6 · The paper itself

Abstract

A limited number of patients with lung squamous cell carcinoma (SCC) benefit clinically from molecular targeted drugs because of a lack of targetable driver alterations. We aimed to understand the prevalence and clinical significance of lysine-specific demethylase 5D (KDM5D) copy number loss in SCC and explore its potential as a predictive biomarker for ataxia-telangiectasia and Rad3-related (ATR) inhibitor treatment. We evaluated KDM5D copy number loss in 173 surgically resected SCCs from male patients using fluorescence in situ hybridization. KDM5D copy number loss was detected in 75 of the 173 patients (43%). Genome-wide expression profiles of the transcription start sites (TSSs) were obtained from 17 SCCs, for which the cap analysis of gene expression assay was performed, revealing that upregulated genes in tumors with the KDM5D copy number loss are associated with 'cell cycle', whereas downregulated genes in tumors with KDM5D copy number loss were associated with 'immune response'. Clinicopathologically, SCCs with KDM5D copy number loss were associated with late pathological stage (p = 0.0085) and high stromal content (p = 0.0254). Multiplexed fluorescent immunohistochemistry showed that the number of tumor-infiltrating CD8

Indexed as

Carcinoma, Squamous CellLung NeoplasmsAtaxia Telangiectasia Mutated ProteinsBiomarkersDNA Copy Number VariationsHistone DemethylasesHumansIn Situ Hybridization, FluorescenceLungMaleMinor Histocompatibility AntigensAtaxia Telangiectasia Mutated ProteinsATR protein, humanBiomarkersHistone DemethylasesKDM5D protein, humanMinor Histocompatibility Antigensataxia-telangiectasia and Rad3-related kinaseDNA damage responseKDM5Dsquamous cell carcinoma

Identifiers

PMID37974379
PMCPMC10766025
OpenAlexW4388768494

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.